未登录 An Integrated Nonclinical and Clinical Risk Assessment of the Effects of Investigational ATRi Tuvusertib on QTc Interval in Patients With Solid Tumors ATR抑制剂Tuvusertib对实体瘤患者QTc间期影响的综合非临床与临床风险评估 Mukker, Jatinder Kaur; Yap, Timothy A.; Tolcher, Anthony W.; de Bono, Johann S.; Plummer, Ruth; Grosser, Gary; van Amsterdam, Christoph; Schieferstein, Hanno; Witjes, Han; Diderichsen, Paul Matthias; Krebs-Brown, Axel; Gao, Wei; Strotmann, Rainer; Szucs, Zoltan; Gounaris, Ioannis; Venkatakrishnan, Karthik 分享 收藏
分享 收藏
分享 收藏
分享 收藏
First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP: TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumors (vol 14, 1376551, 2024) Shimizu, Toshio; Powderly, John; Abdul Razak, Albiruni; Lorusso, Patricia; Miller, Kathy D.; Kao, Steven; Kongpachith, Sarah; Tribouley, Catherine; Graham, Michelle; Stoll, Brian; Patel, Maulik; Sahtout, Mohammad; Blaney, Martha; Leibman, Rachel; Golan, Talia; Tolcher, Anthony 分享 收藏
First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumors Shimizu, Toshio; Powderly, John; Abdul Razak, Albiruni; Lorusso, Patricia; Miller, Kathy D.; Kao, Steven; Kongpachith, Sarah; Tribouley, Catherine; Graham, Michelle; Stoll, Brian; Patel, Maulik; Sahtout, Mohammad; Blaney, Martha; Leibman, Rachel; Golan, Talia; Tolcher, Anthony 分享 收藏
分享 收藏
Preliminary safety and clinical activity of ASP3082, a first-in-class, KRAS G12D selective protein degrader in adults with advanced pancreatic (PC), colorectal (CRC), and non-small cell lung cancer (NSCLC) 一流的KRAS G12D选择性蛋白降解剂ASP3082在成人晚期胰腺癌 (PC)，结直肠癌 (CRC) 和非小细胞肺癌 (NSCLC) 中的初步安全性和临床活性 Park, W.; Kasi, A.; Spira, A. I.; Berlin, J. D.; Wang, J. S.; Herzberg, B.; Kuboki, Y.; Kitano, S.; Pelster, M.; Goldman, J. W.; Morgensztern, D.; Kondo, S.; Janne, P. A.; Fujii, H.; Lee, H-J.; Gill, S.; Saci, A.; Lorusso, P.; Tolcher, A. W. 分享 收藏
Translational, PK, PD, and immunophenotyping analyses of tuvusertib plus niraparib in a phase Ib open-label multicenter dose-escalation study in patients with advanced solid tumors (DDRiver Solid Tumors 301) 转化性研究、药代动力学（PK）、药效动力学（PD）和免疫表型分析：Tuvusertib联合Niraparib在晚期实体瘤患者中的 Ib 期开放标签多中心剂量递增研究（DDRiver Solid Tumors 301） Tolcher, A. W.; Yap, T. A.; Plummer, R.; Sommerhalder, D.; Rodon, J.; Lagonera, M.; Bergmann, P.; Perez, V. Sanchez; Wohlfeil, N.; Wang, D.; Mukker, J. Kaur; Sessa, G.; Manginelli, A.; de Bono, J. S. 分享 收藏
分享 收藏
A Phase I/IIa clinical trial (TranStar101) to evaluate the safety, tolerability and pharmacokinetics of OSEMITAMAB administered as monotherapy or in combination with nivolumab or standard of care in patients with locally advanced or metastatic solid tumors Janjigian, Yelena; Tolcher, Anthony; Mehta, Rutika; Cecchini, Michael; Van Tine, Brian; Kundranda, Madappa; Olatunji, Alese; Patel, Manish R.; Berlin, Jordan; Rocha-Lima, Caio Max Sao Pedro; Monga, Dulabh; Ben George; Scott, Aaron; Xia, Zhenzhong; Elsafy, Mohamed; Jones, Erikca; Yao, Zhenling; Qi, Chuan; Germa, Caroline; Gabrail, Nash 分享 收藏
First-in-human dose-expansion study of NBF-006, a novel investigational siRNA targeting GSTP, in patients with KRAS-mutated non-small cell lung cancer Bazhenova, Lyudmila; Mamdani, Hirva; Chiappori, Alberto; Spira, Alexander; Iams, Wade; Tolcher, Anthony; Barve, Minal; Gabayan, Afshin; Vandross, Andrae; Cina, Cima; Cohen-Arazi, Yael; Albaugh, Zachary; Huynh, Annie; Gullbo, Joachim; Zabludoff, Sonya 分享 收藏
First-in-human trial of TIGIT inhibitor M6223 as monotherapy or in combination with bintrafusp alfa (BA) in patients (pts) with advanced solid unresectable tumors Naing, Aung; McKean, Meredith; Tolcher, Anthony; Victor, Anja; Hu, Ping; Mehr, Keyvan Tadjalli; Kitzing, Thomas; Holland, Daniel; Richter, Emilia; Siu, Lillian 分享 收藏
Phase Ib trial of ATR inhibitor (ATRi) tuvusertib plus ATM inhibitor (ATMi) lartesertib (M4076) in patients (pts) with advanced solid tumors Siu, Lillian L.; Cabanas, Elena Garralda; Boni, Valentina; Tolcher, Anthony W.; Garcia, Enrique Sanz; Fuentes-Antras, Jesus; Saavedra, Omar; Vagge, Deepthi S.; Locatelli, Giuseppe; Gunhan, Burak Kursad; Pennock, Gregory; Mukker, Jatinder Kaur; Gounaris, Ioannis; Yap, Timothy A. 分享 收藏
分享 收藏
Phase 1 study of MDM2 antagonist ASTX295 in patients with solid tumors with wild-type TP53 Dumbrava, Ecaterina E.; Iwamoto, Fabio M.; Agulnik, Mark; Milhem, Mohammed; Tolcher, Anthony W.; Chugh, Rashmi; Demeure, Michael J.; Mita, Alain; Demel, Kurt; Diamond, Mark; Mirakhur, Beloo; Wilson, Laksmi; Oganesian, Aram; Chan, Danna; Keer, Harold N.; Taylor, Jason; Sims, Martin J.; Biondo, Andrea; Jueliger, Simone; Spira, Alexander 分享 收藏
Pharmacokinetic/biomarker (PK/ BMx) analysis of the toll- like receptor 7 and 8 (TLR7/8) agonist EIK1001 in phase 1 studies in participants (Pts) with solid tumors Rasco, Drew; Patel, Manish; Johnson, Melissa; Tolcher, Anthony; Sommerhalder, David; Hamid, Omid; Alistar, Angela; Kochan, Jarema; Kurland, Etah; Wang, Meihua; Cho, Carolyn; Rebello, Sam 分享 收藏
分享 收藏
First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors Yap, Timothy A.; Tolcher, Anthony W.; Plummer, Ruth; Mukker, Jatinder Kaur; Enderlin, Marta; Hicking, Christine; Grombacher, Thomas; Locatelli, Giuseppe; Szucs, Zoltan; Gounaris, Ioannis; de Bono, Johann S. 分享 收藏
Phase I Study of GS-3583, an FMS-like Tyrosine Kinase 3 Agonist Fc Fusion Protein, in Patients with Advanced Solid Tumors Tolcher, Anthony W.; Brody, Joshua D.; Rajakumaraswamy, Nishanthan; Kuhne, Michelle; Trowe, Torsten; Dauki, Anees M.; Pai, Shantheri; Han, Ling; Lin, Kai-Wen; Petrarca, Michael; Kummar, Shivaani 分享 收藏
.png){kind=icon}
.png){kind=icon}
.png)
ANNALS OF ONCOLOGY.png)
.png){kind=icon}
分享.png){kind=icon}
收藏